Skip to main content

BeNeLuxA

Hauptnavigation

  • News
    • Joint HTA assessment of Zolgensma
    • Statement on CAR-T
    • No “lottery for life”
    • Archive
  • About
    • Beneluxa initiative
    • Mandate and organisation
    • Benefits
  • Activities
    • Horizon Scanning
    • Health Technology Assessment
      • HTA procedures within the Beneluxa Initiative
    • Information Sharing
      • Patient registries
    • Pricing and reimbursement
  • Documents
    • Background documents
    • About Beneluxa - press releases
    • About Beneluxa - statements
    • Templates
  • Contact
  • xclose
Contact
contact us
Activities
Symbolic chart
Beneluxa initiative
Map with IE

The Beneluxa Initiative aims to ensure sustainable access
to innovative medicine at affordable cost for our patients.

Joint HTA assessment of Zolgensma 

On May 19 the European Commission granted conditional approval for Zolgensma (onasemnogene abeparvovec) for the treatment of patients with 5q spinal muscular atrophy (SMA) with a bi-allelic mutation…
more: Joint HTA assessment of Zolgensma 

Beneluxa Position Statement on CAR-T

Because of considerable upfront costs, CAR-T(°) treatments are in the process of being reviewed by a number of countries to determine whether they represent value for money. Many countries have…
more: Beneluxa Position Statement on CAR-T

No “lottery for life” - Statement by Beneluxa Health Ministers addressing the global managed access program designed by Novartis and Avexis

BRUSSELS, Jan 30th, 2020. The Health Ministers of Belgium, the Netherlands, Luxembourg, Austria and Ireland have strong reservations in relation to the plans of Novartis and AveXis to let chance…
more: No “lottery for life” - Statement by Beneluxa Health Ministers addressing the global managed access program designed by Novartis and Avexis

Veranstaltungen

Alle Veranstaltungen

Contact

info@beneluxa.org

Info

Disclaimer

Links

About

Back to top